Author

Kaijun Wang

Observed name: K. Wang

Institution: BeOne Medicines (Switzerland)

Observed institutions: Second Affiliated Hospital of Zhejiang University, BeOne Medicines (Switzerland), Zhejiang University

ORCID: 0009-0005-0537-978X

Observed ORCID: 0009-0005-0537-978X

OpenAlex ID: A5111040026

Neonatal vaccination with Bacillus Calmette‐Guérin elicits long‐term protection in mouse‐allergic responses

2008 · H. Shen, H. Huang, et al. · Allergy · 45

OA02.03 The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI

2019 · S. Lu, Q. Wang, et al. · Journal of Thoracic Oncology · 15

Comparative effectiveness and safety of tislelizumab versus other anti–PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non–small cell lung cancer: Systematic literature review and network meta-analysis

2025 · Nicolas Girard, Ji-Youn Han, et al. · Lung Cancer · 6

1262P Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033

2020 · C. Zhou, J. Feng, et al. · Annals of Oncology · 6

147P PD-L1 expression influenced by osimertinib treatment in advanced EGFR T790M-positive non-small cell lung cancer patients

2021 · Y. Yu, L. Xia, et al. · Journal of Thoracic Oncology · 2

MA 11.03 Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)

2017 · J. Wang, Y. Cheng, et al. · Journal of Thoracic Oncology · 2

EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs

2022 · S. Lu, Y. Zhang, et al. · Journal of Thoracic Oncology · 1

P45.08 Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China

2021 · S. Lu, Q. Zhou, et al. · Journal of Thoracic Oncology · 1

JCSE01.14 Higher Prevalence of EGFR Mutations Significantly Correlates with Lower PD-L1 Expression in Chinese Lung Adenocarcinoma

2019 · S. Wen, Y. Jiang, et al. · Journal of Thoracic Oncology · 1

Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons

2025 · Jaffer A. Ajani, Kaijun Wang, et al. · Advances in Therapy

P76.28 Phase II Study of the Efficacy of the EGFR Inhibitor Mefatinib in Patients with Advanced EGFR-mutant NSCLC

2021 · P. Wang, Y. Li, et al. · Journal of Thoracic Oncology

Pcn191 Clinical Outcomes and Adherence Among Nsclc Patients Using Pemetreed as First-line Treatment Before and After Critical Disease Insurance (cdi) Policy Implementation

2019 · J.Y. Zhou, C.Y. Xie, et al. · Value in Health

Works count: 12

Citation count: 79

H-index: 4

I10-index: 2